LYEL 8-K 2026-11-04

Lyell Immunopharma, Inc. (LYEL) 8-K dated 2026-11-04 — accession 0001193125-26-446317.

Lyell Immunopharma, Inc. (LYEL) is a biotechnology company listed on US.

Lyell Immunopharma, Inc. filed a 8-K on 2026-11-04. Accession 0001193125-26-446317.

This 8-K covers: Unregistered share sale (Item 3.02). SEC EDGAR holds the official filing and its exhibits.

Latest reported LYEL revenue for 2025-12-31 was $36.0K. Net income was -$274.4M. Revenue was down 41.0% from 2024-12-31 to 2025-12-31. LYEL currently screens at market cap $143.5M.

Not investment advice. The LYEL SEC hub lists recent forms. The stock page is the research view.